Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?

被引：4
作者：
Grinda, T. [1 ]
Delaloge, S. [1 ,2 ]
机构：
[1] Gustave Roussy, Dept Canc Med, Villejuif, France
[2] Paris Saclay Univ, Gustave Roussy, INSERM, U931,Canc Biomarkers, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷 / 11期
关键词：
DOUBLE-BLIND; BRCA; OLAPARIB; THERAPY;
D O I：
10.1016/j.annonc.2020.09.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1432 / 1434
页数：3
相关论文
共 16 条
  • [1] [Anonymous], 2020, J CLIN ONCOL S
  • [2] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
  • [3] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
    Coleman, R. L.
    Fleming, G. F.
    Brady, M. F.
    Swisher, E. M.
    Steffensen, K. D.
    Friedlander, M.
    Okamoto, A.
    Moore, K. N.
    Ben-Baruch, N. Efrat
    Werner, T. L.
    Cloven, N. G.
    Oaknin, A.
    DiSilvestro, P. A.
    Morgan, M. A.
    Nam, J. -H.
    Leath, C. A., III
    Nicum, S.
    Hagemann, A. R.
    Littell, R. D.
    Cella, D.
    Baron-Hay, S.
    Garcia-Donas, J.
    Mizuno, M.
    Bell-McGuinn, K.
    Sullivan, D. M.
    Bach, B. A.
    Bhattacharya, S.
    Ratajczak, C. K.
    Ansell, P. J.
    Dinh, M. H.
    Aghajanian, C.
    Bookman, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) : 2403 - 2415
  • [4] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Coleman, Robert L.
    Oza, Amit M.
    Lorusso, Domenico
    Aghajanian, Carol
    Oaknin, Ana
    Dean, Andrew
    Colombo, Nicoletta
    Weberpals, Johanne, I
    Clamp, Andrew
    Scambia, Giovanni
    Leary, Alexandra
    Holloway, Robert W.
    Amenedo Gancedo, Margarita
    Fong, Peter C.
    Goh, Jeffrey C.
    O'Malley, David M.
    Armstrong, Deborah K.
    Garcia-Donas, Jesus
    Swisher, Elizabeth M.
    Floquet, Anne
    Konecny, Gottfried E.
    McNeish, lain A.
    Scott, Clare L.
    Cameron, Terri
    Maloney, Lara
    Isaacson, Jeff
    Goble, Sandra
    Grace, Caroline
    Harding, Thomas C.
    Raponi, Mitch
    Sun, James
    Lin, Kevin K.
    Giordano, Heidi
    Ledermann, Jonathan A.
    [J]. LANCET, 2017, 390 (10106) : 1949 - 1961
  • [5] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2091 - 2102
  • [6] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Dieras, Veronique
    Han, Hyo S.
    Kaufman, Bella
    Wildiers, Hans
    Friedlander, Michael
    Ayoub, Jean-Pierre
    Puhalla, Shannon L.
    Bondarenko, Igor
    Campone, Mario
    Jakobsen, Erik H.
    Jalving, Mathilde
    Oprean, Cristina
    Palacova, Marketa
    Park, Yeon Hee
    Shparyk, Yaroslav
    Yanez, Eduardo
    Khandelwal, Nikhil
    Kundu, Madan G.
    Dudley, Matthew
    Ratajczak, Christine K.
    Maag, David
    Arun, Banu K.
    [J]. LANCET ONCOLOGY, 2020, 21 (10) : 1269 - 1282
  • [7] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Farmer, H
    McCabe, N
    Lord, CJ
    Tutt, ANJ
    Johnson, DA
    Richardson, TB
    Santarosa, M
    Dillon, KJ
    Hickson, I
    Knights, C
    Martin, NMB
    Jackson, SP
    Smith, GCM
    Ashworth, A
    [J]. NATURE, 2005, 434 (7035) : 917 - 921
  • [8] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon-Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke
    Tortora, Giampaolo
    Alguel, Hana
    O'Reilly, Eileen M.
    McGuinness, David
    Cui, Karen Y.
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) : 317 - 327
  • [9] Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
    Hu, Zheng
    Li, Zan
    Ma, Zhicheng
    Curtis, Christina
    [J]. NATURE GENETICS, 2020, 52 (07) : 701 - +
  • [10] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    Litton, J. K.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Goncalves, A.
    Diab, S.
    Woodward, N.
    Goodwin, A.
    Yerushalmi, R.
    Roch, H.
    Im, Y-H
    Eiermann, W.
    Quek, R. G. W.
    Usari, T.
    Lanzalone, S.
    Czibere, A.
    Blum, J. L.
    Martin, M.
    Ettl, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (11) : 1526 - 1535
12